Literature DB >> 29507108

RGC32 Promotes Bleomycin-Induced Systemic Sclerosis in a Murine Disease Model by Modulating Classically Activated Macrophage Function.

Chenming Sun1, Shi-You Chen2.   

Abstract

Systemic sclerosis (SSc) is a multisystem autoimmune disorder that is characterized by inflammation and fibrosis in the skin and internal organs. Previous studies indicate that inflammatory cells and cytokines play essential roles in the pathogenesis of SSc; however, the mechanisms that underlie the inflammation-driven development of SSc are not fully understood. In this study, we show that response gene to complement 32 (RGC32) is abundantly expressed in mouse macrophages in the early stage of bleomycin-induced SSc. Importantly, RGC32 is required to induce the inflammatory response during the onset of SSc, because RGC32 deficiency in mice significantly ameliorates skin and lung sclerosis and inhibits the expression of inflammatory mediators inducible NO synthase (iNOS) and IL-1β in macrophages. RGC32 appears to be a novel regulator for the differentiation of classically activated macrophages (M1 macrophages). IFN-γ and LPS stimulation induces RGC32 expression in primary peritoneal macrophages and bone marrow-derived macrophages. RGC32 deficiency impairs the polarization of M1 macrophages and attenuates iNOS and IL-1β production. Mechanistically, RGC32 interacts with NF-κB proteins and promotes iNOS and IL-1β expression by binding to their promoters. Collectively, our data reveal that RGC32 promotes the onset of SSc by regulating the inflammatory response of M1 macrophages, and it may serve as a promising therapeutic target for treating SSc.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29507108      PMCID: PMC5893351          DOI: 10.4049/jimmunol.1701542

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

Review 1.  The myofibroblast in pulmonary fibrosis.

Authors:  Sem H Phan
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

Review 2.  Systemic sclerosis refractory disease: from the skin to the heart.

Authors:  Isabel Almeida; Raquel Faria; Pedro Vita; Carlos Vasconcelos
Journal:  Autoimmun Rev       Date:  2011-05-07       Impact factor: 9.754

3.  Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis.

Authors:  Victoria K Shanmugam; Donna R Swistowski; Nicole Saddic; Hong Wang; Virginia D Steen
Journal:  Clin Rheumatol       Date:  2011-05-27       Impact factor: 2.980

4.  Increased CD226 Expression on CD8+ T Cells Is Associated with Upregulated Cytokine Production and Endothelial Cell Injury in Patients with Systemic Sclerosis.

Authors:  Masahiro Ayano; Hiroshi Tsukamoto; Kentaro Kohno; Naoyasu Ueda; Atsushi Tanaka; Hiroki Mitoma; Mitsuteru Akahoshi; Yojiro Arinobu; Hiroaki Niiro; Takahiko Horiuchi; Koichi Akashi
Journal:  J Immunol       Date:  2015-06-24       Impact factor: 5.422

5.  Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.

Authors:  Takashi Taniguchi; Yoshihide Asano; Kaname Akamata; Shinji Noda; Takehiro Takahashi; Yohei Ichimura; Tetsuo Toyama; Maria Trojanowska; Shinichi Sato
Journal:  Arthritis Rheumatol       Date:  2015-02       Impact factor: 10.995

Review 6.  Experimental models of dermal fibrosis and systemic sclerosis.

Authors:  Jérôme Avouac; Muriel Elhai; Yannick Allanore
Journal:  Joint Bone Spine       Date:  2012-07-28       Impact factor: 4.929

7.  Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis.

Authors:  Nobuyo Higashi-Kuwata; Masatoshi Jinnin; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Faith C Muchemwa; Yuji Yonemura; Yoshihiro Komohara; Motohiro Takeya; Hiroaki Mitsuya; Hironobu Ihn
Journal:  Arthritis Res Ther       Date:  2010-07-05       Impact factor: 5.156

8.  Type 1 angiotensin receptors on macrophages ameliorate IL-1 receptor-mediated kidney fibrosis.

Authors:  Jian-dong Zhang; Mehul B Patel; Robert Griffiths; Paul C Dolber; Phillip Ruiz; Matthew A Sparks; Johannes Stegbauer; Huixia Jin; Jose A Gomez; Anne F Buckley; William S Lefler; Daian Chen; Steven D Crowley
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

9.  Telomerase reverse transcriptase acts in a feedback loop with NF-κB pathway to regulate macrophage polarization in alcoholic liver disease.

Authors:  Xiao-Qin Wu; Yang Yang; Wan-Xia Li; Ya-Hui Cheng; Xiao-Feng Li; Cheng Huang; Xiao-Ming Meng; Bao-Ming Wu; Xin-Hua Liu; Lei Zhang; Xiong-Wen Lv; Jun Li
Journal:  Sci Rep       Date:  2016-01-04       Impact factor: 4.379

10.  FSP1(+) fibroblast subpopulation is essential for the maintenance and regeneration of medullary thymic epithelial cells.

Authors:  Lina Sun; Chenming Sun; Zhanfeng Liang; Hongran Li; Lin Chen; Haiying Luo; Hongmei Zhang; Pengbo Ding; Xiaoning Sun; Zhihai Qin; Yong Zhao
Journal:  Sci Rep       Date:  2015-10-08       Impact factor: 4.379

View more
  8 in total

1.  IL-33/Regulatory T-Cell Axis Suppresses Skin Fibrosis.

Authors:  Se Yun Cheon; Jong Ho Park; Amir H Ameri; Richard T Lee; Rosalynn M Nazarian; Shadmehr Demehri
Journal:  J Invest Dermatol       Date:  2022-03-25       Impact factor: 7.590

2.  Regulator of Cell Cycle Protein (RGCC/RGC-32) Protects against Pulmonary Fibrosis.

Authors:  Irina G Luzina; Violeta Rus; Virginia Lockatell; Jean-Paul Courneya; Brian S Hampton; Rita Fishelevich; Alexander V Misharin; Nevins W Todd; Tudor C Badea; Horea Rus; Sergei P Atamas
Journal:  Am J Respir Cell Mol Biol       Date:  2022-02       Impact factor: 7.748

3.  LncRNA GAS5 attenuates fibroblast activation through inhibiting Smad3 signaling.

Authors:  Rui Tang; Yung-Chun Wang; Xiaohan Mei; Ning Shi; Chenming Sun; Ran Ran; Gui Zhang; Wenjing Li; Kevin F Staveley-O'Carroll; Guangfu Li; Shi-You Chen
Journal:  Am J Physiol Cell Physiol       Date:  2020-05-06       Impact factor: 4.249

4.  Response by Cui et al to Letter Regarding Article, "RGC-32 (Response Gene to Complement 32) Deficiency Protects Endothelial Cells From Inflammation and Attenuates Atherosclerosis".

Authors:  Xiao-Bing Cui; Jun-Na Luan; Kun Dong; Sisi Chen; Yongyi Wang; Wendy T Watford; Shi-You Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-06       Impact factor: 8.311

5.  Pumping the Brakes on Pulmonary Fibrosis: A New Role for Regulator of Cell Cycle.

Authors:  Loka Raghu Kumar Penke; Gina Torres Matias; Megan N Ballinger
Journal:  Am J Respir Cell Mol Biol       Date:  2022-02       Impact factor: 6.914

Review 6.  Role of RGC-32 in multiple sclerosis and neuroinflammation - few answers and many questions.

Authors:  Alexandru Tatomir; Jacob Cuevas; Tudor C Badea; Dafin F Muresanu; Violeta Rus; Horea Rus
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

7.  RGCC balances self-renewal and neuronal differentiation of neural stem cells in the developing mammalian neocortex.

Authors:  Zhenming Guo; Mengxia Chen; Yiming Chao; Chunhai Cai; Liangjie Liu; Li Zhao; Linbo Li; Qing-Ran Bai; Yanxin Xu; Weibo Niu; Lei Shi; Yan Bi; Decheng Ren; Fan Yuan; Shuyue Shi; Qian Zeng; Ke Han; Yi Shi; Shan Bian; Guang He
Journal:  EMBO Rep       Date:  2021-07-29       Impact factor: 9.071

Review 8.  Response Gene to Complement 32 in Vascular Diseases.

Authors:  Xiao-Bing Cui; Shi-You Chen
Journal:  Front Cardiovasc Med       Date:  2018-09-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.